Recurrent Wilms Tumor and Other Childhood Kidney Tumors Clinical Trial
Official title:
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Renal Tumor Project: Application of Array-Based Methods and Next Generation Sequencing to Identify Candidate Molecular Targets for High-Risk Wilms Tumors
This research study is studying biomarkers in tissue samples from patients with high-risk Wilms tumor. Studying samples of tissue from patients with cancer in the laboratory may help doctors to learn more about changes that occur in DNA and identify biomarkers related to cancer.
OBJECTIVES:
I. To assess genomic gains and losses in high risk renal tumors, including up to 80
favorable histology Wilms tumors that relapse (RFHWT), 50 anaplastic Wilms tumors (UHWT), 15
clear cell sarcomas of the kidney (CCSK), and 40 rhabdoid tumors (RT) using a high density
genetic platform to survey for recurrent copy number variations and allelic imbalances. II.
To define transcription patterns within 80 RFHWT, 50 UHWT, 15 CCSK, and 40 RT using a high
throughput platform for global gene expression. III. To define DNA methylation patterns
within 80 RFHWT, 50 UHWT, 15 CCSK, and 40 RT using a high throughput platform. IV. To
identify genetic mutations involved in the pathogenesis of Wilms tumor, and in the
development of relapse and anaplasia through the study of 80 RFHWT, 50 UHWT, 15 CCSK, and 40
RT using next generation sequencing tools.
V. To facilitate the integration of the above databases and allow meaningful access by
investigators through the infrastructure provided by TARGET, including its data portal and
associated caBIG tool.
OUTLINE: This is a multicenter study.
Archived tumor tissue samples are analyzed for DNA copy number determination, gene
expression, DNA methylation, and genomic re-sequencing by array-based methods, including PCR
analysis, methylation-specific reverse transcriptase-PCR (RT-PCR), and quantitative RT-PCR.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01305200 -
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
|
Phase 3 | |
Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT01614808 -
Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor
|
N/A | |
Completed |
NCT01502410 -
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00831844 -
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 | |
Completed |
NCT01586104 -
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
|
N/A | |
Completed |
NCT00897637 -
Gene Expression Profiles to Categorize Wilms Tumors
|
N/A | |
Completed |
NCT00309907 -
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT00331643 -
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00012181 -
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
|
Phase 1 |